CANP3; CANPL3; LGMD2; LGMD2A; nCL-1; p94
The CAPN3 gene is associated with autosomal recessive and dominant limb-girdle muscular dystrophy type 2A (LGMD2A) (MedGen UID: 358391; PMID:27259757).
Order this gene as a single gene test.
Invitae tests that include this gene:
Pathogenic variants in CAPN3 cause an estimated 6% of LGMD overall, and as much as 80% of recessive LGMD in populations with founder mutations, such as the Basque population in Spain.
The CAPN3 gene encodes Calpain-3, a calcium-activated neutral protease. This enzyme is expressed in the sarcomere and plays a role in the proper function of the dysferlin complex.
Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).
Our sequence analysis covers clinically important regions of each gene, including coding exons, +/- 10 base pairs of adjacent intronic sequence in the transcript listed below. In addition, analysis covers the select non-coding variants specifically defined in the table below. Any variants that fall outside these regions are not analyzed. Any specific limitations in the analysis of these genes are also listed in the table below.
Our analysis detects most intragenic deletions and duplications at single exon resolution. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. If you are requesting the detection of a specific single-exon copy number variation, please contact Client Services before placing your order.
|Gene||Transcript reference||Sequencing analysis||Deletion/Duplication analysis|